Patents by Inventor Raffaella Garzia

Raffaella Garzia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical aerosol composition
    Patent number: 8420058
    Abstract: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: April 16, 2013
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION
    Publication number: 20120184502
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 19, 2012
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara MALVOLTI, Raffaella Garzia
  • Optimised formulation of tobramycin for aerosolization
    Patent number: 8168598
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: May 1, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
    Patent number: 8142763
    Abstract: The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is stainless steel, anodized aluminum, or lined with an inert organic coating and which contain a formulation which comprises ipratropium bromide.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: March 27, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION
    Publication number: 20110212912
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Application
    Filed: May 6, 2011
    Publication date: September 1, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Optimised formulation of tobramycin for aerosolization
    Patent number: 7939502
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: May 10, 2011
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • PRESSURISED METERED DOSE INHALERS (MDI)
    Publication number: 20110100361
    Abstract: The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: David LEWIS, David GANDERTON, Brian MEAKIN, Paolo VENTURA, Gaetano BRAMBILLA, Raffaella GARZIA
  • Pressurised metered dose inhalers (MDI)
    Patent number: 7740463
    Abstract: The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: June 22, 2010
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION
    Publication number: 20100098642
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Application
    Filed: December 18, 2009
    Publication date: April 22, 2010
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Optimised formulation of tobramycin for aerosolization
    Patent number: 7696178
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 13, 2010
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • PHARMACEUTICAL AEROSOL COMPOSITION
    Publication number: 20090311196
    Abstract: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.
    Type: Application
    Filed: August 26, 2009
    Publication date: December 17, 2009
    Applicant: Chiesi Farmaceutici S.p.A
    Inventors: David LEWIS, Davis GANDERTON, Brian MEAKIN, Paolo VENTURA, Gaetano BRAMBILLA, Raffaella GARZIA
  • Pharmaceutical aerosol composition
    Patent number: 7601336
    Abstract: A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.
    Type: Grant
    Filed: May 12, 2003
    Date of Patent: October 13, 2009
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • PRESSURISED METERED DOSE INHALERS (MDI)
    Publication number: 20080247965
    Abstract: The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005.
    Type: Application
    Filed: June 4, 2008
    Publication date: October 9, 2008
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: David LEWIS, David GANDERTON, Brian MEAKIN, Paolo VENTURA, Gaetano BRAMBILLA, Raffaella GARZIA
  • PRESSURISED METERED DOSE INHALERS (MDI)
    Publication number: 20080115782
    Abstract: The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is stainless steel, anodized aluminum, or lined with an inert organic coating and which contain a formulation which comprises ipratropium bromide.
    Type: Application
    Filed: January 31, 2008
    Publication date: May 22, 2008
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: David LEWIS, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • Pressurised metered dose inhalers (MDI)
    Patent number: 7347199
    Abstract: The invention relates to the use of pressurized metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminum or lined with an inert organic coating; and to compositions to be delivered with said MDIs.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: March 25, 2008
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • Pressurised metered dose inhalers (MDI)
    Patent number: 7223381
    Abstract: The invention relates to the use of pressurized metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodized aluminum or lined with an inert organic coating; and to compositions to be delivered with said MDIs.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: May 29, 2007
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
  • Optimized formulation of tobramycin for aerosolization
    Patent number: 6987094
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: January 17, 2006
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Formulations of steroid solutions for inhalatory administration
    Patent number: 6967017
    Abstract: The present invention relates to optimized formulations of antiinflammatory steroids for nebulisation and a process for the preparation thereof. More particularly, the invention relates to formulations for monodose or multidose vials in the form of preservative-free stable solutions of a more acceptable osmolarity, which can effectively be nebulised with the nebulisers currently available on the market and are well-tolerated by patients.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: November 22, 2005
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia, Gaetano Brambilla, Paolo Chiesi
  • Optimised formulation of tobramycin for aerosolization
    Publication number: 20050163722
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Application
    Filed: March 18, 2005
    Publication date: July 28, 2005
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Pressurised metered dose inhalers (MDI)
    Publication number: 20050142071
    Abstract: The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.
    Type: Application
    Filed: February 18, 2005
    Publication date: June 30, 2005
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: David Lewis, David Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia